AVEO Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From AVEO Pharmaceuticals, Inc.
With the integration with new parent LG Chem having gone "smoothly," AVEO Oncology is accelerating R&D efforts by beginning a pivotal Phase III trial with a combination of its novel candidate for head and neck cancer.
A number of recent significant transactions in the South Korean biopharma space indicate some emerging trends as the sector develops and expands internationally. Scrip takes a look at the over-arching themes in M&A activity over the past few years and how these may differ from those being observed globally.
Companies making blood-based cancer screening tests face a number of barriers to full market entry but getting a foothold of any kind can be the start of a path towards greater ultimate uptake.
Large Korean pharma firms’ first-quarter earnings were mostly mixed on a range of diverse factors such as solid prescription sales and impacts from acquisitions, with some even looking to space for new business opportunities.
- Drug Discovery Technologies
Drug Discovery Technologies
- Other Names / Subsidiaries
- AVEO Oncology
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.